Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

Key Takeaways

• FDA warns ImmunityBio for false Anktiva claims.
• ImmunityBio shares tumble 26% after warning.
• Merck to buy Terns for $6.7 billion, 31% premium.
• Shionogi purchases Apnimed’s JV stake for $150 million.
• Insurance benefit structures hinder GLP‑1 affordability.

Summary

The FDA issued a warning letter to ImmunityBio for misleading promotional claims about its bladder‑cancer drug Anktiva, triggering a roughly 26 percent drop in the company’s shares and giving it 15 days to submit a corrective plan. In parallel, Merck announced a $6.7 billion acquisition of Terns Pharmaceuticals at a 31 percent premium to secure the CML candidate TERN‑701 ahead of Keytruda’s 2028 patent expiration. Shionogi is buying Apnimed’s 50 percent stake in their sleep‑science joint venture for a total of $150 million. A new commentary argues that insurance benefit design, not list price, is the primary barrier to GLP‑1 affordability.

Pulse Analysis

The FDA’s Office of Prescription Drug Promotion has once again demonstrated its willingness to police off‑label marketing, this time targeting ImmunityBio’s Anktiva campaign. By labeling a bladder‑cancer therapy as a pan‑cancer cure and suggesting a single‑dose regimen, the company crossed the line between education and deception, prompting a warning letter and a sharp 26 percent share decline. For biotech firms, the episode serves as a cautionary tale: promotional materials must align tightly with the FDA‑approved label, or risk not only regulatory sanctions but also eroding investor trust.

Merck’s $6.7 billion acquisition of Terns Pharmaceuticals reflects a broader shift toward bolstering late‑stage oncology pipelines ahead of key patent cliffs. TERN‑701, a next‑generation chronic myeloid leukemia candidate, offers Merck a potential successor to Keytruda as the blockbuster’s exclusivity expires in 2028. Paying a 31 percent premium underscores the premium placed on differentiated assets that can sustain revenue streams. The deal also signals that large pharma continues to favor strategic buyouts over internal R&D, especially when the target brings a clear regulatory path and market‑ready product.

The commentary on GLP‑1 access highlights that list‑price cuts alone will not solve affordability for commercially insured patients. Accumulator and maximizer clauses, coupled with high‑deductible health plans, shift the cost burden back to consumers, often resulting in hundreds of dollars of out‑of‑pocket expense each month. This structural issue forces manufacturers to reconsider rebate strategies and may spur policy discussions around benefit‑design reform. Until insurers redesign benefit structures, even aggressive price reductions are likely to have limited impact on real‑world patient access, reshaping how pharma approaches pricing and market entry.